BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down - Here's Why

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $8.43, but opened at $7.77. BioCryst Pharmaceuticals shares last traded at $7.15, with a volume of 1,709,944 shares changing hands.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Barclays increased their price target on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an "equal weight" rating in a research note on Tuesday, August 6th. Royal Bank of Canada restated an "outperform" rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. StockNews.com raised BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, August 6th. Finally, JMP Securities raised their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $14.17.

BioCryst Pharmaceuticals Price Performance

The business's 50-day moving average price is $7.86 and its two-hundred day moving average price is $6.93. The company has a market capitalization of $1.52 billion, a P/E ratio of -9.79 and a beta of 1.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.11. The business had revenue of $109.30 million for the quarter, compared to analyst estimates of $98.30 million. The company's revenue for the quarter was up 34.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.24) EPS. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of BioCryst Pharmaceuticals by 15.4% during the 4th quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company's stock worth $106,405,000 after acquiring an additional 2,371,401 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in BioCryst Pharmaceuticals by 13.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 138,074 shares of the biotechnology company's stock valued at $701,000 after purchasing an additional 15,894 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at $327,000. Inspire Investing LLC lifted its position in BioCryst Pharmaceuticals by 9.7% during the 1st quarter. Inspire Investing LLC now owns 69,466 shares of the biotechnology company's stock worth $353,000 after buying an additional 6,141 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of BioCryst Pharmaceuticals by 200.8% during the 1st quarter. Russell Investments Group Ltd. now owns 58,725 shares of the biotechnology company's stock worth $298,000 after buying an additional 39,205 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.